Table 2 Important agents currently enrolling patients in clinical trials for systemic lupus erythematosus as of November 2010
From: Advances in drug therapy for systemic lupus erythematosus
Target | Trial | Comment |
|---|---|---|
T cells | NCT007744752 | Abatacept |
| Â | NCT00774943 | Amgen 557 ICOS inhibitor |
B cells | NCT00660881 | Epratuzumab (anti-CD22) |
| Â | NCT00624338 | Atacicept blocks BlyS and APRIL |
| Â | NCT01162681 | A-623 blocks BlyS and APRIL |
| Â | NCT01205348 | LY2127399 blocks BlyS |
Toleragen | NCT01085097 | Laquinomod |
| Â | NCT01135459 | Lupuzor tolerizes splicosome |
Innate immunity | NCT00962832 | Rontalizumab inhibits IFN-α |
|  | NCT01164917 | Amgen 811 targets IFN-γ |
|  | NCT00960362 | NNCO152 targets IFN-α |
|  | NCT01031836 | MEDI-545 targets IFN-α |
Cell surface receptor | NCT0077194 | Rapamycin targets mTOR |